Information for Healthcare Providers

Why choose EsopredictTM?

As a busy gastroenterologist, you understand the importance of getting timely patient insights that lead to actionable next steps. Even the best standard of care plan that includes regularly scheduled endoscopies and biopsies may not detect small morphological changes.

With EsopredictTM, you can quickly and easily identify your Barrett’s esophagus patients’ risk of progressing to esophageal cancer.

EsopredictTM empowers gastroenterologists to provide a proactive, tailored approach to Barrett’s esophagus treatment.

  • Uses a standard of care biopsy sample obtained during a patient’s routine screening or follow up endoscopy
  • Assesses methylation levels of 4 genes to risk-stratify patients who are at a higher risk or lower risk for developing high grade dysplasia or esophageal cancer
  • Detects cancer signals that otherwise might not be identified until later stages of progression
  • Provides predictive information, independent of clinical variables such as dysplasia or Barrett’s esophagus segment length
barrets esophagus population